Stemchymal® for Polyglutamine Spinocerebellar Ataxia

Subjects who have been enrolled in any kind of cell therapy within six months prior to screening visit (Visit 1).

Female subjects who have a positive pregnancy test result.

Subjects who have had severe vital organ diseases, including but not limited to cardiac (e.g., heart failure), liver (e.g., acute hepatic failure or chronic liver cirrhosis), lung (e.g., respiratory failure) and renal (e.g., hemodialysis or peritoneal dialysis) diseases, within six months prior to screening visit (Visit 1).

Subjects with immunological disorders (e.g., systemic lupus erythematosus), within six months prior to screening visit (Visit 1).